New Delhi, Aug. 12 -- Hyderabad-based Biophore India Pharmaceuticals Pvt Ltd is strengthening its bulk drugs manufacturing with an acquisition, VCCircle has gathered.

Around the same time, the pharma company has hived off a subsidiary that supplies to the diagnostics industry, VCCircle has learnt.

Biophore, which offers R&D in drug discovery, has acquired an Indore-based sterile injectable manufacturing facility from US based generic drugmaker Par Health for an undisclosed amount. The deal is expected to close in the fourth quarter of 2026, subject to various conditions.

Separately, VCCircle gathered that the drugmaker also sold its subsidiary Vivere Imaging, which provides contrast media for diagnostic imaging. However, a person close to the company's plans explained that the pharmaceutical company's shareholders are still invested in Vivere. The details of the deal could not be ascertained.

"The [newly acquired] Indore facility adds specialised sterile injectable capabilities to our global manufacturing network and strengthens our ability to serve the increasing demand for complex injectable products," said Jagadeesh Babu Rangisetty, co-founder & group managing director, Biophore, in a statement.

Rangisetty refused to comment on the sale of the subsidiary Vivere Imaging.

The Indore facility brings sterile fill-finish capabilities into Biophore's global finished dose production network for complex generic and proprietary injectable products. The facility is approved by the US Food and Drug Administration (FDA) and is located in a special economic zone.

The acquisition also complements Biophore's non-parenteral manufacturing network. Non-parenteral administration of drugs does not involve puncturing of the skin.

Founded in 2007 by Rangisetty and Manik Reddy Pullagurla, Biophore focusses on developing, manufacturing and supplying medicines including niche and complex medicines for regulated markets. The company has four US FDA and EU approved API manufacturing facilities, and an R&D lab housing 400 scientists with varied expertise. The company offers high-entry-barrier products across oncology and contrast media.

As of FY26, the company generated close to Rs 600 crore in operating revenue, roughly 30% up from the preceding year, while its net profit rose to Rs 118-119 crore, VCCircle has gathered. Its operating margin improved to almost 33% in FY26, VCCircle learnt, compared to 27.4% a year ago, as per VCCEdge.

Published by HT Digital Content Services with permission from VC Circle.